Citations

Clear

3138 citation(s) found for "Smith, AM".

Indications for cerebral revascularization for moyamoya syndrome in pediatric sickle cell disease determined by Delphi methodology
Robert, Adam , Adelson, P. David, Lang, Shih‐Shan , Grabb, Paul A. , Greene, Stephanie , Leonard, Jeffrey, Magge, Suresh N. , Marupudi, Neena I. , Sillero, Rafael de Oliveira , Smith, Edward R. , Smith, Jodi L. , Strahle, Jennifer M. , Vadivelu, Sudhakar , Wellons, John C. , Wrubel, David, Hatem, Asmaa, Moody, C, Han, Sabrina H. , Millican, Nicklaus , Dain, Aleksandra S. , Beslow, Lauren A. , Aldana, Philipp R. , Montaser, Alaa, Smith, Edward , Hanel, Ricardó A. , Johnston, James M. , Piatt, Joseph H. , Hatem, Asmaa, Montaser, Alaa S. , Pederson, John M.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | July 24, 2024 | Volume: 34 | Issue: 4 | Pages: 402-413

10.3171/2024.5.peds2426 | PMID 39029127 Get It

OBJECTIVE Cerebral revascularization surgery (CRS) has been used to prevent stroke in children with sickle cell disease (SCD) and cerebral vasculopathy (e.g., moyamoya syndrome). While results suggest that it may be an effective treatment, surgical indications have not been well defined. This study sought to determine indications for offering revascularization surgery in centers with established sickle cell programs in the US. METHODS Three sequential surveys utilizing the Delphi methodology were administered to neurosurgeons participating in the Stroke in Sickle Cell Revascularization Surgery study. Respondents were presented with clinical scenarios of patients with SCD and varying degrees of ischemic presentation and vasculopathy, and the group’s agreement to offer surgical revascularization was measured. Consensus was defined as ≥ 75% similar responses. RESULTS The response rate to all 3 surveys was 100%. Seventeen neurosurgeons from 16 different centers participated. The presence of moyamoya collaterals (MMCs) and arterial stenosis matching an ischemic distribution yielded the strongest recommendations to offer surgery. There was consensus to offer revascularization in the presence of MMCs and at least 50% arterial stenosis matching an ischemic distribution. In contrast, there was no consensus to offer revascularization with 50%–70% stenosis not matching an ischemic presentation in the absence of MMCs. The presence of the ivy sign in the distribution of the stenotic artery also contributed to the consensus to offer surgery in certain scenarios. CONCLUSIONS There were several clinical scenarios that attained consensus to offer surgery; the strongest was moderate to severe arterial stenosis that matched the distribution of ischemic presentation in the presence of MMCs. Radiological findings of decreased cerebral flow or perfusion also facilitated attaining consensus to offer surgery. The findings of this study reflect expert opinion about questions that deserve prospective clinical research. Determination of indications for CRS can guide clinical practice and aid the design of prospective studies.
Impact of Workplace Violence Against Emergency Medical Services (EMS)
McGuire, Sarayna S. , Clements, Casey M. , Lampman, Michelle A. , Smith, Olivia A, McGuire, Sarayna S , Smith, Olivia A.

Mayo Clinic

Prehospital Emergency Care | July 23, 2024 | Volume: 29 | Issue: 2 | Pages: 129-137

10.1080/10903127.2024.2381218 | PMID 39042823 Get It

Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model
Leuzy, Antoine , Villemagne, Victor L. , Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Boada, Merçé , Charil, Arnaud , Collins, Emily C. , Collins, Jessica , Cullen, Nicholas , Gunn, Roger N. , Higuchi, Makoto , Hostetler, Eric D., Hutchison, R. Matthew , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Karten, Yashmin, Marquié, Marta , Mathotaarachchi, Sulantha , Mintun, Mark A., Pappas, Ioannis , Petersen, Ronald C. , Rabinovici, Gil D. , Stephens, Andrew , Whittington, Alex , Carrillo, Marı́a C., Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, Hartmuth C. , Doré, Vincent , Carrillo, María C. , Jack, Clifford R , Boada, Merce , Rabinovici, Gil D , Doré, Vincent , Rakêt, Lars Lau , Tonietto, Mattéo , Bohórquez, Sandra Sanabria , Betthauser, Tobey J. , Iaccarino, Leonardo , Insel, Philip S. , Johnson, Sterling C. , Ossenkoppele, Rik , Rosa-Neto, Pedro , Schwarz, Christopher G. , Smith, Ruben , Sivakumaran, Sudhir , Rowe, Christopher Cleon , Hansson, Oskar

Mayo Clinic

Alzheimer's & Dementia | July 23, 2024 | Volume: 20 | Issue: 9 | Pages: 5833-5848

10.1002/alz.13908 | PMID 39041435 Get It

Abstract INTRODUCTION Tau‐positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instrumentation, and methods of analysis. METHODS Using head‐to‐head data from five cohorts with tau PET radiotracers designed to target tau deposition in AD, we tested a joint propagation model (JPM) to harmonize quantification (units termed “CenTauR” [CTR]). JPM is a statistical model that simultaneously models the relationships between head‐to‐head and anchor point data. JPM was compared to a linear regression approach analogous to the one used in the amyloid PET Centiloid scale. RESULTS A strong linear relationship was observed between CTR values across brain regions. Using the JPM approach, CTR estimates were similar to, but more accurate than, those derived using the linear regression approach. DISCUSSION Preliminary findings using the JPM support the development and adoption of a universal scale for tau‐PET quantification. Highlights Tested a novel joint propagation model (JPM) to harmonize quantification of tau PET. Units of common scale are termed “CenTauRs”. Tested a Centiloid‐like linear regression approach. Using five cohorts with head‐to‐head tau PET, JPM outperformed linearregressionbased approach. Strong linear relationship was observed between CenTauRs values across brain regions.
A Multiomics, Molecular Atlas of Breast Cancer Survivors
Bauer, Brent A. , Schmidt, Caleb M., Ruddy, Kathryn J. , Meydan, Cem , Schmidt, Julian C., Smith, S. , Couch, Fergus J., Earls, John C. , Dudley, Joel T. , Mason, Christopher E. , Zhang, Bodi, Phipps, Stephen M., Schmidt, Michael A. , Dudley, Joel T , Mason, Christopher E , Schmidt, Michael A , Meydan, Cem , Olson, Janet E. , Price, Nathan D.

Mayo Clinic

Metabolites | July 22, 2024 | Volume: 14 | Issue: 7 | Pages: 396

10.3390/metabo14070396 | PMID 39057719 Get It

Breast cancer imposes a significant burden globally. While the survival rate is steadily improving, much remains to be elucidated. This observational, single time point, multiomic study utilizing genomics, proteomics, targeted and untargeted metabolomics, and metagenomics in a breast cancer survivor (BCS) and age-matched healthy control cohort (N = 100) provides deep molecular phenotyping of breast cancer survivors. In this study, the BCS cohort had significantly higher polygenic risk scores for breast cancer than the control group. Carnitine and hexanoyl carnitine were significantly different. Several bile acid and fatty acid metabolites were significantly dissimilar, most notably the Omega-3 Index (O3I) (significantly lower in BCS). Proteomic and metagenomic analyses identified group and pathway differences, which warrant further investigation. The database built from this study contributes a wealth of data on breast cancer survivorship where there has been a paucity, affording the ability to identify patterns and novel insights that can drive new hypotheses and inform future research. Expansion of this database in the treatment-naïve, newly diagnosed, controlling for treatment confounders, and through the disease progression, can be leveraged to profile and contextualize breast cancer and breast cancer survivorship, potentially leading to the development of new strategies to combat this disease and improve the quality of life for its victims.
Treatment options for necrotizing scleritis in rheumatoid arthritis patients
Kraker, Jessica A. , Smith, Wendy M.

Mayo Clinic

Expert Review of Ophthalmology | July 19, 2024 | Volume: 19 | Issue: 5 | Pages: 357-377

10.1080/17469899.2024.2382148 Get It

IFTA Foci Density: An Unrecognized Highly Prognostic Measurement of Fibrosis in Kidney Transplant Biopsies
Đenić, Aleksandar , Rule, Andrew D., Park, Walter D. , Smith, Byron H. , Mejia, Mateo Velasquez , Kukla, Aleksandra , Grande, Joseph P. , Smith, Byron , Denic, Aleksandar , Park, Walter , Rule, Andrew D. , Stegall, Mark D.

Mayo Clinic

Kidney360 | July 18, 2024 | Volume: 5 | Issue: 9 | Pages: 1341-1349

10.34067/kid.0000000000000514 | PMID 39024036 Get It

Key Points Morphometry allows for a more prognostic multidimensional quantification of interstitial fibrosis and tubular atrophy (IFTA) in kidneys than does visual inspection. The density of IFTA foci is determined by dividing the number of contiguous IFTA patches in the kidney cortex by the area of cortex. Higher density of IFTA foci significantly predicted renal allograft failure beyond %IFTA and other biopsy and clinical characteristics. Background Contraction of interstitial fibrosis and tubular atrophy (IFTA) may cause %IFTA to under-represent the severity of nephron loss. Higher density of IFTA foci is an important predictor of progressive CKD in native kidneys independent of %IFTA. Methods We studied kidney transplant recipients transplanted between 2000 and 2013 who had a 5-year surveillance kidney biopsy and subsequent follow-up. Banff ci score (interstitial fibrosis) was obtained from the pathology reports. After digitizing the biopsies, we traced cortex area and each distinct IFTA focus on a single trichrome-stained section. Percent IFTA area and IFTA foci density (count of IFTA foci/cortex area) were calculated. Cox models assessed the risk of death-censored graft failure after the 5-year biopsy with Banff ci score, morphometric %IFTA, and IFTA foci density. Results There were 58 death-censored allograft failures among 835 kidney recipients during the 5 years of follow-up. Biopsies from grafts that failed had higher mean Banff ci score (1.5 versus 0.7, P < 0.0001), %IFTA (22.6% versus 7.0%, P < 0.0001), and IFTA foci density (1.3/mm 2 versus 0.4/mm 2 , P < 0.0001). After adjusting for other Banff scores or clinical variables, Banff ci did not correlate with allograft failure, but both higher %IFTA (hazard ratio = 1.56, P < 0.0001) and higher IFTA foci density (hazard ratio = 2.34, P < 0.0001) did. All but four allograft failures by 10 years had biopsies in the top quartile of either %IFTA or IFTA foci density at 5 years. A model using just these two morphometric measures without clinical characteristics resulted in a c-statistic of 0.891 with respect to allograft failure. Conclusions Morphometric characterization of IFTA foci density is a strong predictor of death-censored allograft failure not captured in current Banff classification for grading of kidney fibrosis.
Outcomes of Early Thrombotic Microangiopathy in Renal Transplantation
Mour, Girish , Ninan, Jacob , Butterfield, Duke, Zhang, Nan , Nair, S. , Smith, Maxwell L. , Ryan, Margaret , Reddy, Kunam S. , Heilman, Raymond L. , Butterfield, Richard , Mour, Girish K , Butterfield, Richard J , Nair, Sumi S , Smith, Maxwell , Reddy, Kunam S

Mayo Clinic

Clinical Transplantation | July 18, 2024 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/ctr.15373 | PMID 39023085 Get It

ABSTRACTBackgroundAlternate complement dysregulation postrenal transplantation can result in thrombotic microangiopathy (TMA). There is a scarcity of data regarding outcomes based on the timing of TMA post‐transplant, coupled with a lack of follow‐up biopsy findings post TMA diagnosis. This study aims to assess allograft and patient outcomes in individuals developing early TMA, defined within 4 months post‐transplantation, and explore any differences in follow‐up surveillance biopsies compared to a non‐TMA group.DesignThis is a single center retrospective study between January 1, 2002 and October 10, 2019. Patients who developed TMA within 4 months post‐transplantation were compared to a propensity matched non‐TMA group.ResultsThirty‐one patients developed TMA within 4 months of renal transplantation. Index TMA biopsy featured noticeable glomerular, and vascular lesions along with acute tubular injury. Four‐month surveillance biopsy showed significant glomerulitis, transplant glomerulopathy and chronic interstitial fibrosis as compared to non‐TMA group. However, at 1 year, these differences were no longer significant. There was no significant difference in patient survival (TMA vs. non‐TMA,p = 0.083); however, death censored graft survival was significantly lower in the TMA group (p < 0.001). TMA patients had a significantly lower estimated glomerular filtration rate at 4 months and at 1 year as compared to the non‐TMA group.ConclusionEarly onset TMA post renal transplant leads to decreased renal function and lower graft survival. Early recognition and prompt treatment may help in reducing the adverse outcomes.
Fair and Just Opportunity: Streamlining COVID-19 Extracorporeal Membrane Oxygenation Referrals on a Statewide Platform to Enhance Equity
Villarroel, Lisa, Arabía, Francisco A. , Tams, Erin M., Hu, Chengcheng , Smith, L.T., Molitor, Mark , Chapital, Alyssa B. , Padiyar, J., Riley, Robert D. , Mosier, Jarrod , Villarroel, Lisa R , Molitor, Mark S , Chapital, Alyssa B , Padiyar, Josna P , Mosier, Jarrod M , Smith, Luke T., Dalton, Heidi J.

Mayo Clinic

Annals of the American Thoracic Society | July 16, 2024 | Volume: 21 | Issue: 10 | Pages: 1375-1378

10.1513/annalsats.202310-907ip | PMID 39012175 Get It

The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder
Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Linder, Brian J , Cameron, Anne P. , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Mayo Clinic

Neurourology and Urodynamics | July 16, 2024 | Volume: 43 | Issue: 8 | Pages: 1742-1752

10.1002/nau.25532 | PMID 39010271 Get It

AbstractPurposeThe purpose of this guideline is to provide evidence‐based guidance to clinicians of all specialties on the evaluation, management, and treatment of idiopathic overactive bladder (OAB). The guideline informs the reader on valid diagnostic processes and provides an approach to selecting treatment options for patients with OAB through the shared decision‐making process, which will maximize symptom control and quality of life, while minimizing adverse events and burden of disease.MethodsAn electronic search employing OVID was used to systematically search the MEDLINE and EMBASE databases, as well as the Cochrane Library, for systematic reviews and primary studies evaluating diagnosis and treatment of OAB from January 2013 to November 2023. Criteria for inclusion and exclusion of studies were based on the Key Questions and the populations, interventions, comparators, outcomes, timing, types of studies and settings (PICOTS) of interest. Following the study selection process, 159 studies were included and were used to inform evidence‐based recommendation statements.ResultsThis guideline produced 33 statements that cover the evaluation and diagnosis of the patient with symptoms suggestive of OAB; the treatment options for patients with OAB, including Noninvasive therapies, pharmacotherapy, minimally invasive therapies, invasive therapies, and indwelling catheters; and the management of patients with BPH and OAB.ConclusionOnce the diagnosis of OAB is made, the clinician and the patient with OAB have a variety of treatment options to choose from and should, through shared decision‐making, formulate a personalized treatment approach taking into account evidence‐based recommendations as well as patient values and preferences.
Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years
O’Sullivan, Ciara C. , Vierkant, Robert A. , Larson, Nicole L. , Smith, Mary Lou , Chauhan, Cynthia, D’Andre, Stacy D. , Jatoi, Aminah , Ruddy, Kathryn J. , Vierkant, Robert A , Couch, Fergus J. , Olson, Janet E.

Mayo Clinic

Cancers | July 9, 2024 | Volume: 16 | Issue: 14 | Pages: 2494

10.3390/cancers16142494 | PMID 39061134 Get It

Background: There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs are critical. Aims: Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80−). Methods: In 12/2021, a REDCap survey was electronically circulated to 6918 persons enrolled in the Mayo Clinic Breast Disease Registry. The survey asked about concerns and satisfaction with multiple aspects of BC care. Results: Overall, 2437 participants responded (35% response rate); 202 (8.3%) were P80+. P80+ were less likely to undergo local regional and systemic therapies vs. P80− (p < 0.01). Notably, P80+ were significantly less satisfied with information about the short and long-term side effects of BC therapies and managing toxicities. P80+ were also less likely to have participated in a clinical trial (p < 0.001) or to want to do so in the future (p = 0.0001). Conclusions: Although P80+ experienced less anxiety and symptom-related distress compared with P80−, they were significantly less satisfied with information regarding the side effects of BC therapies and their management. P80+ were significantly less likely to have participated in a clinical trial or be open to considering this option. Future studies should address educational needs pertaining to side effects and barriers to research participation in P80+.